SUBSCRIBE
SUBSCRIBE

Nimbus Therapeutics

NEWS
Pharm Country
BioSpace Movers and Shakers: March 22
Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
March 21, 2019
 · 
6 min read
 · 
Alex Keown
Business
Biotech Movers and Shakers for Oct. 8
Transition continues as biotech companies continue to adjust their leadership ranks and strengthen the members of their organization representing and overseeing the companies. Here is a look at some of those transitions.
October 5, 2018
 · 
4 min read
 · 
Alex Keown
Genetown
Nimbus Therapeutics Raises Another $65 Million from Lilly, Bill Gates, Pfizer and Others
Nimbus Therapeutics, raised an additional $65 million in financing.
June 5, 2018
 · 
3 min read
 · 
Mark Terry
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Genetown
MA Life Science Growing: Backed By Eli Lilly and Pfizer, Nimbus Therapeutics Bankrolls $43 Million
March 18, 2015
 · 
2 min read
Load More
JOBS
IN THE PRESS
Genetown
Anagenex and Nimbus Announce a Multi-Target Collaboration to Discover Small Molecule Therapeutics for Multiple Indications
December 18, 2023
 · 
3 min read
Genetown
Nimbus Therapeutics Presents Positive Preliminary Data from Clinical Trial of HPK1 Inhibitor in Solid Tumors at SITC Annual Meeting
October 31, 2023
 · 
3 min read
Genetown
Nimbus Therapeutics Secures $210M Private Financing to Advance Next Wave of Tech-Enabled Small Molecule Medicines
September 6, 2023
 · 
3 min read
Pharm Country
Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda
February 14, 2023
 · 
4 min read
Deals
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
February 8, 2023
 · 
7 min read
Deals
Nimbus Therapeutics Announces Closing of Takeda’s Acquisition of TYK2 Subsidiary
February 8, 2023
 · 
2 min read
Drug Development
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
December 13, 2022
 · 
19 min read
Deals
Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
December 13, 2022
 · 
3 min read
Drug Development
Nimbus Therapeutics Announces Positive Topline Results for Phase 2b Clinical Trial of Allosteric TYK2 Inhibitor in Psoriasis
November 30, 2022
 · 
4 min read
Business
Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer
October 26, 2022
 · 
2 min read
Load More